SML4059
Elagolix sodium
≥98% (HPLC)
别名:
NBI56418, (R)-4-{2-[5-(2-Fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyric acid sodium salt, Elagolix sodium salt, NBI 56418, NBI-56418
登录 查看组织和合同定价。
选择规格
变更视图
关于此项目
Assay:
≥98% (HPLC)
Form:
powder
Storage condition:
desiccated
Quality Segment
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
white to beige
solubility
H2O: 2 mg/mL, clear
storage temp.
-10 to -25°C
SMILES string
CC1=C(C2=C(C(OC)=CC=C2)F)C(N(C(N1CC3=C(C=CC=C3F)C(F)(F)F)=O)C[C@@H](C4=CC=CC=C4)NCCCC(O[Na])=O)=O
Biochem/physiol Actions
Orally active human gonadotropin releasing hormone (GnRH)/luteinizing hormone releasing hormone (LHRH) receptor (GnRHR, LHRHR) antagonist.
Elagolix is an orally active, potent, high-affinity human gonadotropin-releasing hormone (GnRH)/luteinizing hormone-releasing hormone (LH-RH) receptor (GnRHR, LHRHR) antagonist (Ki = 0.9 nM/human, 3.3 nM/monkey, 4.4 µM/rat) that effectively blocks GnRH-induced inositol phosphate production in RBL-1 hGnRH-R transfectants (IC50 = 1.5 nM against 6 nM GnRH). Oral administration in castrated male cynomolgus macaques effectively reduces circulating LH in a reversible manner in vivo (75% reduction 8h post 30 mg/kg p.o.).
Elagolix is an orally active, potent, high-affinity human gonadotropin-releasing hormone (GnRH)/luteinizing hormone-releasing hormone (LH-RH) receptor (GnRHR, LHRHR) antagonist (Ki = 0.9 nM/human, 3.3 nM/monkey, 4.4 µM/rat) that effectively blocks GnRH-induced inositol phosphate production in RBL-1 hGnRH-R transfectants (IC50 = 1.5 nM against 6 nM GnRH). Oral administration in castrated male cynomolgus macaques effectively reduces circulating LH in a reversible manner in vivo (75% reduction 8h post 30 mg/kg p.o.).
Disclaimer
Hygroscopic
signalword
Warning
hcodes
Hazard Classifications
Repr. 2
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable